X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Generic Version of Medrol

    Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Version of Medrol

    Fig extract for healthy blood sugar levels

    Fig extract for healthy blood sugar levels

    Novartis ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Generic Version of Medrol

    Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Version of Medrol

    Fig extract for healthy blood sugar levels

    Fig extract for healthy blood sugar levels

    Novartis ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Rotavirus Vaccination Decreases Diarrhea Hospitalizations Among Kids

Yuvraj_pawp by Yuvraj_pawp
7th July 2014
in Americas, News

Since the introduction of routine rotavirus vaccination in 2006, rates of diarrhea-related hospitalizations in US children have decreased significantly.

 

Diarrhea-related health care use among young children in the United States has dramatically decreased since the implementation of rotavirus vaccines, the results of a recent study indicate. In addition, the study estimates that more than $900 million in health care costs have been avoided due to vaccination.

 

In 2006, routine vaccination with the pentavalent rotavirus vaccine (RV5) was recommended for infants by the Advisory Committee on Immunization Practices, and the monovalent rotavirus vaccine (RV1) was added to the recommendation in 2008. The current study, published online on June 9, 2014, in Pediatrics, analyzed data from the 2001-2011 Truven Health MarketScan Commercial Claims and Encounters Database to evaluate reductions in diarrhea-associated health care use among children younger than 5 years after the introduction of both vaccines. The retrospective analysis also assessed the direct and indirect effectiveness of the vaccines.

 

The researchers of the study analyzed annual RV5 and RV1 vaccine coverage and compared rates of diarrhea-associated hospitalizations, emergency department visits, and outpatient visits during a pre-vaccine period (2001 to 2006) and during a post-vaccine period (2007 to 2011). Rates of diarrhea-associated health care use were also compared among vaccinated and unvaccinated children, and among unvaccinated children in pre- and post-vaccine periods.

 

By the end of 2010, 58% of children included in the study had been vaccinated with at least 1 dose of RV5 and 5% had received at least 1 dose of RV1. The results indicated that diarrhea-associated hospitalizations were significantly lower for each of the 4 seasons after the vaccines were introduced, and emergency department and outpatient visits were significantly lower in all seasons, except for the 2008-2009 season. Compared with the average rate of hospitalizations for diarrhea from 2001 to 2006, hospitalization rates fell by 75% in 2007-2008, 60% in 2008-2009, 94% in 2009-2010, and 80% in 2010-2011.

 

During the 2010-2012 season, the rate of hospitalizations decreased by 92% among children vaccinated with RV5 and by 96% among those who received RV1 when compared with unvaccinated children. Emergency department visits also significantly declined by 31% among children who received RV5 and by 33% among those who received RV1 when compared with unvaccinated children.  In addition, hospitalization rates among unvaccinated children significantly decreased by 50% in 2007-2008, 77% in 2009-2010, and 25% in 2010-2011 when compared with the average rate during the pre-vaccine period.

 

Overall, the researchers estimated that 176,587 hospitalizations, 242,335 emergency department visits, and 1,116,869 outpatient visits were avoided among children younger than 5 years from 2007 to 2011. Based on these numbers, they estimated that health care costs were reduced by $924 million during this period.

 

“Both rotavirus vaccines showed comparable effectiveness and long-term protection was documented for RV5,” the authors of the study wrote. “Indirect benefits from vaccination were observed and have amplified the overall impact of the vaccination program.” – See more at: http://www.pharmacytimes.com/news/Rotavirus-Vaccination-Decreases-Diarrhea-Hospitalizations-Among-Kids#sthash.mJ38G9hS.dpuf

 

Tags: America
Previous Post

GenOway offers industry scientists immediate access to EUCOMM conditional KO mouse models

Next Post

Weight-Loss Surgery, Prescriptions More Satisfying for Obese Patients

Related Posts

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases
Drug Development

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

26th November 2019
Elsevier and FDA to work on AI algorithm for drug-induced liver injury
Americas

Elsevier and FDA to work on AI algorithm for drug-induced liver injury

26th November 2019
Lilly to invest $400m to boost manufacturing capacity in US
Americas

Lilly to invest $400m to boost manufacturing capacity in US

26th November 2019
ConvergeHEALTH by Deloitte Launches New Digital Health Ecosystem Platforms at HLTH Conference
News

ConvergeHEALTH by Deloitte Launches New Digital Health Ecosystem Platforms at HLTH Conference

4th November 2019
Foamix Enters Manufacturing Agreement with ASM Aerosol-Service for Topical Foam Treatment
Manufacturing

Foamix Enters Manufacturing Agreement with ASM Aerosol-Service for Topical Foam Treatment

4th November 2019
Finalists revealed for CPhI Worldwides eagerly anticipated 2019 Awards
Manufacturing

Finalists revealed for CPhI Worldwides eagerly anticipated 2019 Awards

4th November 2019
Next Post

Weight-Loss Surgery, Prescriptions More Satisfying for Obese Patients

Latest News

CPhI Worldwide pointing 2020 to be a strong year for pharma
Manufacturing

CPhI Worldwide pointing 2020 to be a strong year for pharma

3rd December 2019
Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases
Drug Development

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

26th November 2019
Elsevier and FDA to work on AI algorithm for drug-induced liver injury
Americas

Elsevier and FDA to work on AI algorithm for drug-induced liver injury

26th November 2019
Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film
FDA Approvals

Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

26th November 2019
Med-Tech Innovation Expo and Medilink UK renew partnership
Drug Development

Med-Tech Innovation Expo and Medilink UK renew partnership

26th November 2019
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In